| 溶解性 | 25°C: DMSO |
| 存贮条件 | 储存温度-20°C |
| 生化机理 | Description:IC50 Value: 1.09 uM (MTT assay in LNCaP-S14 cells) [1]SMIP004 (N-(4-butyl-2-methyl-phenyl) acetamide) is a novel inducer of cancer-cell selective apoptosis of human prostate cancer cells. Unlike SMIP001, SMIP004 was found to downregulate SKP2 and to stabilize p27, although neither SMIP is a proteasome inhibitor.in vitro: Whereas SMIP012 and 016 were moderately toxic in normal fibroblasts, SMIPs 001 and 004 showed substantial cancer cell specificity being at least five times more potent in LNCaP-S14 than in IMR90 cells , treatment with either MG132 or SMIP004 increased p27 half-life to > 6 h [1]. Both SMIP001 and 004 led to a strong increase in the recruitment of p27 to CDK2, while SMIP001 also slightly increased coprecipitation of p21 (Figure 6c). SMIP004 also reduced the amounts of cyclins E and A retrieved with CDK2. This was paralleled by a marked downregulation of cyclins E and A upon SMIP004 treatment. SMIP004 decreased the levels of positive cell cycle regulators, upregulated cyclin-dependent kinase inhibitors, and resulted in G1 arrest, inhibition of colony formation in soft agar, and cell death [2].in vivo: SMIP004 potently inhibits the growth of prostate and breast cancer xenografts in mice [2].Clinical trial: N/A |
SMIP004,SKP2 E3 Ligase 抑制剂
SMIP004 （订货以英文为准）
编号：S124937
CAS号：143360-00-3
分子式：C13H19NO
分子量：205.30
| 产品名称 | SMIP004 |
| 中文名称 | SMIP004,SKP2 E3 Ligase 抑制剂 |
| CAS号 | 143360-00-3 |
| 分子式（M.F.） | C13H19NO |
| 分子量（M.W.） | 205.30 |
| 储存条件 | -20°C储存 |
搜索质检报告(COA)
搜索MSDS
相关产品
¥ 155.00
F903483-100g
¥ 2750.00
sh246789-100kg
¥ 128.00
sh7651-500mL
¥ 128.00
sh8754-500mL
¥ 128.00
sh42798-500mL
党沛 
